Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.04
(
-0.61%
)
Bitcoin
73,867.23
(
-0.10%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 140510

Sunday, 04/22/2012 3:20:28 PM

Sunday, April 22, 2012 3:20:28 PM

Post# of 257253
HCV companies keep cranking out non-nucleoside polymerase inhibitors in spite of the modest results to date for this class; this one is PPI-383 from the private company, Presidio, which also has an NS5A inhibitor (#msg-74622695):

http://finance.yahoo.com/news/presidio-pharmaceuticals-announces-clinical-candidate-060000775.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today